Last C$0.08 CAD
Change Today 0.00 / 0.00%
Volume 216.7K
ATE On Other Exchanges
As of 2:39 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

antibe therapeutics inc (ATE) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - C$0.88
52 Week Low
01/26/15 - C$0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

antibe therapeutics inc (ATE) Related Businessweek News

No Related Businessweek News Found

antibe therapeutics inc (ATE) Details

Antibe Therapeutics Inc. originates, develops, and out-licenses patent-protected pharmaceuticals for pharmaceutical and biotechnology companies. The company’s lead product includes ATB-346, a hydrogen sulfide-releasing derivative of naproxen that is in pre clinical studies for the treatment of acute and chronic joint pain, as well as to treat rheumatoid arthritis, osteoarthritis pain, ankylosing spondylitis, dysmenorrhea, dental pain, and general pain. Its products also comprise ATB-344, an indomethacin derivative to enhance the treatments for the pain associated with gout; ATB-429 for treating inflammatory bowel diseases; and GIC-1001, a hydrogen sulfide-releasing salt of trimebutine to treat irritable bowel syndrome. The company was incorporated in 2009 and is headquartered in Toronto, Canada. Antibe Therapeutics Inc. is a subsidiary of Antibe Holdings Inc.

Founded in 2009

antibe therapeutics inc (ATE) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: C$261.6K
Founder, Chief Scientific Officer and Directo...
Total Annual Compensation: C$261.6K
Chief Financial Officer
Total Annual Compensation: C$201.3K
Chief Development Officer
Total Annual Compensation: C$179.8K
Executive Vice President of Strategic Develop...
Total Annual Compensation: C$12.8K
Compensation as of Fiscal Year 2014.

antibe therapeutics inc (ATE) Key Developments

Antibe Therapeutics Inc. Announces Resignation of Jonathan Ross Goodman from Board of Directors

Antibe Therapeutics Inc. announced that Jonathan Ross Goodman has resigned from the company's Board of Directors, effective February 28, 2015.

Antibe Therapeutics Suspends its Phase I Clinical Trial Due to Safety Concerns

Antibe Therapeutics Inc. announced that it has suspended development of its lead drug, ATB-346, due to safety concerns encountered in its Phase I clinical trial. Safety concerns centered on the finding of significant liver enzyme elevations in one subject in the highest dose cohort. Additional liver enzyme elevations were observed in other subjects in the higher dose cohorts. Antibe is concerned that, when assessed together, these liver enzyme elevations are indicative of potential hepatotoxicity. Pre-clinical studies on ATB-346 provided no indication of potential hepatotoxicity. The company continues to collect and assess data and will report back to the scientific community and the market with further details on its data review and corporate strategy as appropriate.

Antibe Therapeutics Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015

Antibe Therapeutics Inc. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 . Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATE:CN C$0.08 CAD 0.00

ATE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ATE.
View Industry Companies

Industry Analysis


Industry Average

Valuation ATE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTIBE THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at